The clinical utility of newer antidepressant agents: Understanding the role in management of MDD
Whereas MDD is characterized in part by changes in mood, other symptoms can also cause significant impairment, including sexual dysfunction, cognitive impairment, and fatigue. Newer antidepressants are explored with the goal of more optimally treating these non–mood-related symptoms of MDD. The 3 or...
| Main Author: | |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
American Association of Psychiatric Pharmacists
2022-11-01
|
| Series: | Mental Health Clinician |
| Subjects: | |
| Online Access: | https://theijpt.org/doi/pdf/10.9740/mhc.2022.10.309 |
| _version_ | 1797383398043418624 |
|---|---|
| author | Kristin Waters, PharmD, BCPS, BCPP |
| author_facet | Kristin Waters, PharmD, BCPS, BCPP |
| author_sort | Kristin Waters, PharmD, BCPS, BCPP |
| collection | DOAJ |
| description | Whereas MDD is characterized in part by changes in mood, other symptoms can also cause significant impairment, including sexual dysfunction, cognitive impairment, and fatigue. Newer antidepressants are explored with the goal of more optimally treating these non–mood-related symptoms of MDD. The 3 oral antidepressants that have been FDA-approved most recently include vortioxetine, vilazodone, and levomilnacipran. Unique features of these antidepressants are explored through 3 patient cases. |
| first_indexed | 2024-03-08T21:20:22Z |
| format | Article |
| id | doaj.art-7900434659794f89a401d2fb33501062 |
| institution | Directory Open Access Journal |
| issn | 2168-9709 |
| language | English |
| last_indexed | 2024-03-08T21:20:22Z |
| publishDate | 2022-11-01 |
| publisher | American Association of Psychiatric Pharmacists |
| record_format | Article |
| series | Mental Health Clinician |
| spelling | doaj.art-7900434659794f89a401d2fb335010622023-12-21T11:47:45ZengAmerican Association of Psychiatric PharmacistsMental Health Clinician2168-97092022-11-0112530931910.9740/mhc.2022.10.309i2168-9709-12-5-309The clinical utility of newer antidepressant agents: Understanding the role in management of MDDKristin Waters, PharmD, BCPS, BCPP0https://orcid.org/0000-0002-2278-10181 Assistant Clinical Professor, University of Connecticut, Storrs, ConnecticutWhereas MDD is characterized in part by changes in mood, other symptoms can also cause significant impairment, including sexual dysfunction, cognitive impairment, and fatigue. Newer antidepressants are explored with the goal of more optimally treating these non–mood-related symptoms of MDD. The 3 oral antidepressants that have been FDA-approved most recently include vortioxetine, vilazodone, and levomilnacipran. Unique features of these antidepressants are explored through 3 patient cases.https://theijpt.org/doi/pdf/10.9740/mhc.2022.10.309antidepressantsmajor depressive disorderpsychopharmacologytreatment-emergent sexual dysfunctioncognitive impairmentdepression-related fatigue |
| spellingShingle | Kristin Waters, PharmD, BCPS, BCPP The clinical utility of newer antidepressant agents: Understanding the role in management of MDD Mental Health Clinician antidepressants major depressive disorder psychopharmacology treatment-emergent sexual dysfunction cognitive impairment depression-related fatigue |
| title | The clinical utility of newer antidepressant agents: Understanding the role in management of MDD |
| title_full | The clinical utility of newer antidepressant agents: Understanding the role in management of MDD |
| title_fullStr | The clinical utility of newer antidepressant agents: Understanding the role in management of MDD |
| title_full_unstemmed | The clinical utility of newer antidepressant agents: Understanding the role in management of MDD |
| title_short | The clinical utility of newer antidepressant agents: Understanding the role in management of MDD |
| title_sort | clinical utility of newer antidepressant agents understanding the role in management of mdd |
| topic | antidepressants major depressive disorder psychopharmacology treatment-emergent sexual dysfunction cognitive impairment depression-related fatigue |
| url | https://theijpt.org/doi/pdf/10.9740/mhc.2022.10.309 |
| work_keys_str_mv | AT kristinwaterspharmdbcpsbcpp theclinicalutilityofnewerantidepressantagentsunderstandingtheroleinmanagementofmdd AT kristinwaterspharmdbcpsbcpp clinicalutilityofnewerantidepressantagentsunderstandingtheroleinmanagementofmdd |